ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Research



Clinical prolife and outcome in COVID-19 patients on treatment regimen of remdesivir, favipiravir, and non-antiviral drugs

Santoshkumar Ashok Shetti, Manu G, Rekha Walwekar.



Abstract
Download PDF Post

Background: Although various drugs have been used in the treatment of COVID-19 infections, specific drug with good therapeutic outcome is still unclear. They are using remdesivir, favipiravir, ivermectin, azithromycin, and so on.

Aim and Objectives: This study aimed to evaluate the clinical profile of patients treated with different regimens and their outcome in improvement or morbidity of patients.

Materials and Methods: We conducted a cross-sectional questionnaire-based study after approval by the institutional ethics committee. Data were collected from case files of COVID-19-positive patients treated in COVID-19 ward in Bharati Hospital, Sangli. We collected the data as per our protocol proforma as – routine covid treatment with remdesivir, favipiravir and non-antiviral drugs. We analyzed various clinical profiles (presenting complaints), duration of stay in COVID wards, their outcome as improved and discharged, or deaths occurred.

Results: It was observed that majority 54% of patients were from 40 to 50 years’ range. There was male preponderance 64%. Clinical symptoms were fever (92%), cough (85%), sore throat (77%), headache (53%), and breathlessness (10%). Majority of them were diabetes mellitus (51%), obesity (22%), and hypertension. Ventilatory support treatment needed in 18%, rest of them recovered on pharmacotherapy.

Conclusion: One of the highly infectious diseases causing COVID-19 is contagious and transmitted through airborne droplets generated by sneezing, smooching, and coughing. Hence as per WHO and CDC guidelines, wear masks & avoid close contact with infected persons in public place. Vaccines available against COVID-19 Covishield and Covaxin to prevent the severity and to have immunity against COVID should be taken by all.

Key words: COVID-19; Remdesivir; Favipiravir; Antiviral Drugs







Bibliomed Article Statistics

28
29
30
38
18
26
24
23
26
32
34
19
R
E
A
D
S

9

7

11

7

8

7

11

13

15

16

22

5
D
O
W
N
L
O
A
D
S
040506070809101112010203
20252026

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.